OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 07:31:18 23/05/2024 BST | ||
| 4.89 EUR | +0.20% |
|
| Current month | +3.61% | ||
| 1 month | +12.96% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 23/05/24 | 4.89 | +0.20% |
| 22/05/24 | 4.88 | +2.31% |
| 21/05/24 | 4.77 | +1.27% |
| 20/05/24 | 4.71 | +0.43% |
| 17/05/24 | 4.69 | +1.08% |
Delayed Quote Deutsche Boerse AG
Last update May 23, 2024 at 07:31 am
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SH6EJ1 |
| ISIN | DE000SH6EJ19 |
| Date issued | 05/04/2022 |
| Strike | 95.39 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.46 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.89 € |
|---|---|
| Lowest since issue | 1.6 € |
| Spread | 0.01 € |
| Spread % | 0.20% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
42.34
USD
Average target price
53.19
USD
Spread / Average Target
+25.64%
- Stock Market
- Certificates
- Certificat
